Table 2.
Demographic and clinical characteristics of men with PCa in the study region, metropolitan Melbourne and the rest of Victoria
| Study region, n (%) | Metropolitan, n (%) | Rest of Victoria, n (%) | p | |
|---|---|---|---|---|
| Included into the study | 373 (5.2 %) | 2,565 (35.6 %) | 4,266 (59.2 %) | 0.000 |
| Age groups | 0.000 | |||
| < 55 | 24 (6.4 %) | 293 (11.4 %) | 549 (12.9 %) | |
| 56–65 | 117 (31.4 %) | 896 (34.9 %) | 1,551 (36.4 %) | |
| 65–75 | 145 (38.9 %) | 909 (35.4 %) | 1,632 (38.3 %) | |
| > 76 | 87 (23.3 %) | 467 (18.2 %) | 534 (12.5 %) | |
| Age (mean, SD) | 68.6 (8.9) | 66.7 (9.3) | 65.5 (8.8) | 0.000 |
| SEIFA | 0.000 | |||
| Lowest 10 % (0–10 %) | 70 (18.9 %) | 93 (3.6 %) | 217 (5.1 %) | |
| Lowest 11–20 % | 57 (15.4 %) | 68 (2.7 %) | 197 (4.6 %) | |
| Lowest 21–30 % | 9 (2.4 %) | 77 (3.0 %) | 232 (5.5 %) | |
| Lowest 31–40 % | 64 (17.3 %) | 127 (5.0 %) | 392 (9.2 %) | |
| Lowest 41–50 % | 113 (29.9 %) | 160 (6.2 %) | 293 (6.9 %) | |
| Highest 51–60 % | 32 (8.6 %) | 119 (4.6 %) | 291 (6.8 %) | |
| Highest 61–70 % | 18 (4.9 %) | 208 (8.1 %) | 496 (11.7 %) | |
| Highest 71–80 % | 8 (2.2 %) | 325 (12.7 %) | 546 (12.8 %) | |
| Highest 81–90 % | 1 (0.3 %) | 747 (29.0 %) | 907 (21.2 %) | |
| Highest 10 % (91–100 %) | 1 (0.3 %) | 641 (25.0 %) | 695 (16.2 %) | |
| Type of hospital | 0.000 | |||
| Private | 47 (12.6 %) | 1,390 (54.2 %) | 2,822 (66.2 %) | |
| Public | 326 (87.4 %) | 1,175 (45.8 %) | 1,444 (33.8 %) | |
| Method of diagnosis | 0.000 | |||
| TRUS | 285 (76.4 %) | 2,081 (81.1 %) | 3,919 (91.9 %) | |
| TURP | 77 (20.7 %) | 416 (16.2 %) | 291 (6.8 %) | |
| Other | 11 (2.9 %) | 68 (2.7 %) | 56 (1.3 %) | |
| PSA (ng/mL) | 0.000 | |||
| < 4 | 45 (12.1 %) | 427 (16.6 %) | 688 (16.1 %) | |
| 4.01–10 | 176 (47.2 %) | 1,337 (52.1 %) | 2,408 (56.4 %) | |
| 10.01–20 | 74 (19.8 %) | 395 (15.4 %) | 679 (15.9 %) | |
| > 20.01 | 72 (19.3 %) | 301 (11.7 %) | 426 (10.0 %) | |
| Unknown | 6 (1.6 %) | 105 (4.1 %) | 65 (1.5 %) | |
| Gleason score | 0.000 | |||
| < 7 | 155 (41.6 %) | 851 (33.2 %) | 1,641 (38.5 %) | |
| 7 (3 + 4) | 69 (18.6 %) | 736 (28.7 %) | 1,306 (30.6 %) | |
| 7 (4 + 3) | 41 (10.9 %) | 394 (15.4 %) | 535 (12.6 %) | |
| ≥ 8 | 103 (27.6 %) | 577 (22.5 %) | 782 (18.3 %) | |
| Unknown | 5 (1.3 %) | 7 (0.3 %) | 2 (0.0 %) | |
| NCCN risk group | 0.000 | |||
| Low | 73 (19.6 %) | 478 (18.6 %) | 911 (21.4 %) | |
| Intermediate | 113 (30.3 %) | 1,064 (41.5 %) | 1,887 (44.2 %) | |
| High | 97 (26.0 %) | 616 (24.0 %) | 867 (20.3 %) | |
| Very high/Metastatic | 44 (11.8 %) | 133 (5.2 %) | 245 (5.7 %) | |
| Unknown | 46 (12.3 %) | 274 (10.7 %) | 356 (8.3 %) |